TELA Bio, Inc. (TELA) research
TELA Bio, Inc.- Sector
- Healthcare
- Industry
- Medical Devices
- Last price
- $1.14
- As of
TELA Bio, Inc. (TELA): 1 institutional manager tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-29.
As of . Source: SEC EDGAR filings for TELA. Method and limitations.
Share the TELA intelligence card
See the full TELA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for TELA on one page. Preview it with sample data, then open it live with a free account.
Preview the TELA dossierActive signals for TELA
- mediumEARNINGS_MISS
Q2-2026: Missed consensus by 10.0%, EPS $-0.20 vs $-0.1818 estimate
- highINSTITUTIONAL_EXIT
RENAISSANCE TECHNOLOGIES LLC cut 59% of TELA (2026Q1)
- mediumEARNINGS_BEAT
Q3-2025: Beat consensus by 6.4% - EPS $-0.19 vs $-0.203 estimate
- mediumEARNINGS_MISS
Q1-2026: Missed consensus by 9.4% - EPS $-0.21 vs $-0.192 estimate
- mediumEARNINGS_MISS
Q2-2025: Missed consensus by 22.0% - EPS $-0.22 vs $-0.1803 estimate
FREE, NO ACCOUNT
Every signal on TELA, as it fires
You are seeing 5 of 8 signals recorded on TELA since 2026-05-30.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in TELA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP 872381108 · 2026Q2 | $44K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, TELA
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
TELA mentioned in Kresmion daily briefs
TELA against its peers
TELA's operating margin of -42.0% ranks in the 65th percentile of 23 Medical Devices sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | TELA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 80.3M USD | 27.5M USD | 77 | 23 |
| Gross margin | 67.7% | 47.6% | 82 | 18 |
| Operating margin | -42.0% | -59.3% | 65 | 23 |
| Net margin | -48.4% | -66.4% | 56 | 23 |
| Return on equity | -615.1% | -67.6% | 7 | 20 |
Peers (23): OM, RPID, COCH, MDNC, MDAI, XTNT, POSC, MYO, NNOX, SRTS, CVRX, ZOMDF, SNWV, SERA, PAVM, LUNG, LNSR, ELUT, QTI, ARAY, HYPR, NSPR, NSYS. Left out: RTGN (no annual filing), TLTFF (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (TELA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more TELA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to TELAand get the insider, 13F, options, and confluence read in one view.